跳转至内容
Merck
CN
所有图片(1)

文件

安全信息

94687

Supelco

依维莫司

analytical standard

别名:

42-O-(2-羟乙基）雷帕霉素

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C53H83NO14
CAS号:
159351-69-6
分子量:
958.22
MDL编号:
MFCD00929329
UNSPSC代码:
41116107
NACRES:
NA.24

等级

analytical standard

质量水平

100

检测方案

≥75.0% (qNMR)

保质期

limited shelf life, expiry date on the label

应用

clinical testing

格式

neat

储存温度

−20°C

SMILES字符串

O=C(C([C@@]1(O)[C@H](C)CC[C@](C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C2=O)([H])O1)=O)N3[C@H](C(O[C@@]([C@@H](C[C@@]4([H])C[C@@H](OC)[C@H](OCCO)CC4)C)([H])CC([C@H](C)/C=C(C)/[C@@H](O)[C@H]2OC)=O)=O)CCCC3

InChI

1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1

InChI key

HKVAMNSJSFKALM-GKUWKFKPSA-N

基因信息

human ... FKBP1A(2280)

正在寻找类似产品? 访问 产品对比指南

相关类别

一般描述

Everolimus (RAD001), a derivative of rapamycin, is commonly used as a drug for the inhibition of the mTOR pathway, affecting tumor cell division and angiogenesis.

应用

Everolimus may be used as a standard in the following clinical studies:
  • Investigation of its glucose-dependent growth-inhibitory property in breast cancer cell lines.
  • Evaluate its possible antiproliferative effects in human bronchial carcinoids in primary culture.

象形图

Health hazardEnvironment
GHS08,GHS09

警示用语：

Warning

危险分类

Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 2 - Repr. 2 - STOT RE 2

靶器官

Kidney,Testes

WGK

WGK 2

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

监管及禁止进口产品

Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells
Ariaans G, et al.
BMC Cancer, 17(1), 232-232 (2017)
Phosphorylation of 4E-BP1 predicts sensitivity to everolimus in gastric cancer cells
Nishi T, et al.
Cancer letters, 331(2), 220-229 (2013)
Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids
Zatelli CM, et al.
Endocrine-Related Cancer, 17(3), 719-729 (2010)
Cardiac Electrophysiology: From Cell to Bedside, 17(1), 232-232 (2016)

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门